ID   M3K1_HUMAN              Reviewed;        1512 AA.
AC   Q13233;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 4.
DT   12-OCT-2022, entry version 209.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 1;
DE            EC=2.7.11.25;
DE   AltName: Full=MAPK/ERK kinase kinase 1;
DE            Short=MEK kinase 1;
DE            Short=MEKK 1;
GN   Name=MAP3K1; Synonyms=MAPKKK1, MEKK, MEKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-1512, FUNCTION, AND INTERACTION WITH
RP   MAP2K4.
RX   PubMed=9808624; DOI=10.1101/gad.12.21.3369;
RA   Xia Y., Wu Z., Su B., Murray B., Karin M.;
RT   "JNKK1 organizes a MAP kinase module through specific and sequential
RT   interactions with upstream and downstream components mediated by its amino-
RT   terminal extension.";
RL   Genes Dev. 12:3369-3381(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1238-1274.
RC   TISSUE=Leukocyte;
RX   PubMed=8597633; DOI=10.1007/bf00539003;
RA   Vinik B.S., Kay E.S., Fiedorek F.T. Jr.;
RT   "Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and human
RT   chromosome 5.";
RL   Mamm. Genome 6:782-783(1995).
RN   [4]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.m208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK
RT   activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [5]
RP   INTERACTION WITH AXIN1.
RX   PubMed=15262978; DOI=10.1074/jbc.m404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase
RT   activation by Axin and dishevelled through distinct mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH GRIPAP1.
RX   PubMed=17761173; DOI=10.1016/j.febslet.2007.08.008;
RA   Ye B., Yu W.P., Thomas G.M., Huganir R.L.;
RT   "GRASP-1 is a neuronal scaffold protein for the JNK signaling pathway.";
RL   FEBS Lett. 581:4403-4410(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154 AND SER-1043, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   INTERACTION WITH STK38.
RX   PubMed=17906693; DOI=10.1038/sj.onc.1210828;
RA   Enomoto A., Kido N., Ito M., Morita A., Matsumoto Y., Takamatsu N.,
RA   Hosoi Y., Miyagawa K.;
RT   "Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38
RT   (STK38).";
RL   Oncogene 27:1930-1938(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-297; SER-300;
RP   SER-507 AND SER-1018, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275 AND SER-292, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-35; SER-275; THR-285;
RP   SER-292; SER-531; SER-923 AND SER-1018, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-92 AND SER-443.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   VARIANTS SRXY6 PRO-189; ARG-189; ILE-GLN-211 INS AND ARG-616, AND
RP   CHARACTERIZATION OF VARIANTS SRXY6 PRO-189 AND ARG-189.
RX   PubMed=21129722; DOI=10.1016/j.ajhg.2010.11.003;
RA   Pearlman A., Loke J., Le Caignec C., White S., Chin L., Friedman A.,
RA   Warr N., Willan J., Brauer D., Farmer C., Brooks E., Oddoux C., Riley B.,
RA   Shajahan S., Camerino G., Homfray T., Crosby A.H., Couper J., David A.,
RA   Greenfield A., Sinclair A., Ostrer H.;
RT   "Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate
RT   a common signal transduction pathway in human testis determination.";
RL   Am. J. Hum. Genet. 87:898-904(2010).
CC   -!- FUNCTION: Component of a protein kinase signal transduction cascade
CC       (PubMed:9808624). Activates the ERK and JNK kinase pathways by
CC       phosphorylation of MAP2K1 and MAP2K4 (PubMed:9808624). May
CC       phosphorylate the MAPK8/JNK1 kinase (PubMed:17761173). Activates CHUK
CC       and IKBKB, the central protein kinases of the NF-kappa-B pathway
CC       (PubMed:9808624). {ECO:0000269|PubMed:17761173,
CC       ECO:0000269|PubMed:9808624}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.25;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by autophosphorylation on Thr-1400 and
CC       Thr-1412 following oligomerization.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates in
CC       multimolecular complexes through its N-terminus (PubMed:9808624).
CC       Oligomerizes after binding MAP2K4 or TRAF2 (PubMed:9808624). Interacts
CC       with AXIN1 (PubMed:12223491, PubMed:15262978). Interacts (via the
CC       kinase catalytic domain) with STK38 (PubMed:17906693). Interacts with
CC       GRIPAP1 (PubMed:17761173). {ECO:0000269|PubMed:12223491,
CC       ECO:0000269|PubMed:15262978, ECO:0000269|PubMed:17761173,
CC       ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:9808624}.
CC   -!- INTERACTION:
CC       Q13233; P15056: BRAF; NbExp=2; IntAct=EBI-49776, EBI-365980;
CC       Q13233; P61962: DCAF7; NbExp=7; IntAct=EBI-49776, EBI-359808;
CC       Q13233; O75369: FLNB; NbExp=2; IntAct=EBI-49776, EBI-352089;
CC       Q13233; P45985: MAP2K4; NbExp=3; IntAct=EBI-49776, EBI-447868;
CC       Q13233; Q12851: MAP4K2; NbExp=2; IntAct=EBI-49776, EBI-49783;
CC       Q13233; Q93009: USP7; NbExp=2; IntAct=EBI-49776, EBI-302474;
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- DISEASE: 46,XY sex reversal 6 (SRXY6) [MIM:613762]: A disorder of sex
CC       development. Affected individuals have a 46,XY karyotype but present as
CC       phenotypically normal females. {ECO:0000269|PubMed:21129722}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC008937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF042838; AAC97073.1; -; mRNA.
DR   EMBL; U29671; AAB05828.1; -; Genomic_DNA.
DR   CCDS; CCDS43318.1; -.
DR   PIR; G01887; G01887.
DR   RefSeq; NP_005912.1; NM_005921.1.
DR   PDB; 6WHB; X-ray; 1.90 A; A=542-888.
DR   PDBsum; 6WHB; -.
DR   AlphaFoldDB; Q13233; -.
DR   SMR; Q13233; -.
DR   BioGRID; 110378; 151.
DR   DIP; DIP-27520N; -.
DR   ELM; Q13233; -.
DR   IntAct; Q13233; 42.
DR   MINT; Q13233; -.
DR   STRING; 9606.ENSP00000382423; -.
DR   BindingDB; Q13233; -.
DR   ChEMBL; CHEMBL3956; -.
DR   DrugBank; DB06061; AZD-8330.
DR   DrugBank; DB11967; Binimetinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13233; -.
DR   GuidetoPHARMACOLOGY; 2069; -.
DR   GlyGen; Q13233; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13233; -.
DR   PhosphoSitePlus; Q13233; -.
DR   BioMuta; MAP3K1; -.
DR   DMDM; 218512139; -.
DR   SWISS-2DPAGE; Q13233; -.
DR   CPTAC; CPTAC-1046; -.
DR   CPTAC; CPTAC-824; -.
DR   CPTAC; CPTAC-825; -.
DR   CPTAC; CPTAC-826; -.
DR   CPTAC; CPTAC-827; -.
DR   CPTAC; CPTAC-829; -.
DR   CPTAC; CPTAC-830; -.
DR   CPTAC; CPTAC-831; -.
DR   CPTAC; CPTAC-832; -.
DR   EPD; Q13233; -.
DR   jPOST; Q13233; -.
DR   MassIVE; Q13233; -.
DR   MaxQB; Q13233; -.
DR   PaxDb; Q13233; -.
DR   PeptideAtlas; Q13233; -.
DR   PRIDE; Q13233; -.
DR   ProteomicsDB; 59240; -.
DR   Antibodypedia; 3855; 459 antibodies from 35 providers.
DR   DNASU; 4214; -.
DR   Ensembl; ENST00000399503.4; ENSP00000382423.3; ENSG00000095015.6.
DR   GeneID; 4214; -.
DR   KEGG; hsa:4214; -.
DR   MANE-Select; ENST00000399503.4; ENSP00000382423.3; NM_005921.2; NP_005912.1.
DR   UCSC; uc003jqw.5; human.
DR   CTD; 4214; -.
DR   DisGeNET; 4214; -.
DR   GeneCards; MAP3K1; -.
DR   GeneReviews; MAP3K1; -.
DR   HGNC; HGNC:6848; MAP3K1.
DR   HPA; ENSG00000095015; Low tissue specificity.
DR   MalaCards; MAP3K1; -.
DR   MIM; 600982; gene.
DR   MIM; 613762; phenotype.
DR   neXtProt; NX_Q13233; -.
DR   OpenTargets; ENSG00000095015; -.
DR   Orphanet; 242; 46,XY complete gonadal dysgenesis.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   PharmGKB; PA30592; -.
DR   VEuPathDB; HostDB:ENSG00000095015; -.
DR   eggNOG; KOG0198; Eukaryota.
DR   GeneTree; ENSGT00940000159154; -.
DR   HOGENOM; CLU_005805_0_0_1; -.
DR   InParanoid; Q13233; -.
DR   OMA; CDDNFGC; -.
DR   OrthoDB; 797346at2759; -.
DR   PhylomeDB; Q13233; -.
DR   TreeFam; TF105112; -.
DR   BRENDA; 2.7.11.25; 2681.
DR   PathwayCommons; Q13233; -.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; Q13233; -.
DR   SIGNOR; Q13233; -.
DR   BioGRID-ORCS; 4214; 13 hits in 1112 CRISPR screens.
DR   ChiTaRS; MAP3K1; human.
DR   GeneWiki; MAP3K1; -.
DR   GenomeRNAi; 4214; -.
DR   Pharos; Q13233; Tchem.
DR   PRO; PR:Q13233; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q13233; protein.
DR   Bgee; ENSG00000095015; Expressed in buccal mucosa cell and 186 other tissues.
DR   Genevisible; Q13233; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; TAS:Reactome.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   Gene3D; 1.25.10.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR007527; Znf_SWIM.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS50966; ZF_SWIM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..1512
FT                   /note="Mitogen-activated protein kinase kinase kinase 1"
FT                   /id="PRO_0000086240"
FT   DOMAIN          1243..1508
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         338..366
FT                   /note="SWIM-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00325"
FT   ZN_FING         443..492
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          1..37
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          67..181
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          213..304
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          416..436
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          511..532
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          602..624
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          933..972
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1032..1087
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        82..96
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        164..181
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        243..263
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        416..432
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        933..955
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1041..1087
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1369
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         1249..1257
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         1272
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53349"
FT   MOD_RES         154
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         285
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         292
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         300
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         923
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1018
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1043
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         1400
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P53349"
FT   MOD_RES         1412
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P53349"
FT   VARIANT         92
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040680"
FT   VARIANT         189
FT                   /note="L -> P (in SRXY6; increases phosphorylation of the
FT                   downstream target MAPK3/MAPK1 compared to wild-type and
FT                   enhances binding of RHOA to the mutant MAP3K1 complex;
FT                   dbSNP:rs387906788)"
FT                   /evidence="ECO:0000269|PubMed:21129722"
FT                   /id="VAR_065504"
FT   VARIANT         189
FT                   /note="L -> R (in SRXY6; increases phosphorylation of the
FT                   downstream targets MAPK14 and MAPK3/MAPK1 compared to
FT                   wild-type and enhances binding of RHOA to the mutant MAP3K1
FT                   complex; dbSNP:rs387906788)"
FT                   /evidence="ECO:0000269|PubMed:21129722"
FT                   /id="VAR_065505"
FT   VARIANT         211
FT                   /note="V -> VIQ (in SRXY6)"
FT                   /id="VAR_065506"
FT   VARIANT         443
FT                   /note="C -> S"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040681"
FT   VARIANT         616
FT                   /note="G -> R (in SRXY6; dbSNP:rs143853590)"
FT                   /evidence="ECO:0000269|PubMed:21129722"
FT                   /id="VAR_065507"
FT   VARIANT         806
FT                   /note="D -> N (in dbSNP:rs702689)"
FT                   /id="VAR_051636"
FT   VARIANT         906
FT                   /note="V -> I (in dbSNP:rs832582)"
FT                   /id="VAR_051637"
FT   CONFLICT        20
FT                   /note="T -> P (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        37
FT                   /note="P -> R (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        120
FT                   /note="G -> R (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        351
FT                   /note="R -> H (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        845
FT                   /note="S -> SV (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        859
FT                   /note="I -> Y (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        878..902
FT                   /note="DGQQDSFLQASVPNNYLETTENSSP -> QRQQHNSFCRHLFPTTIWKPQRT
FT                   VPL (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        933
FT                   /note="S -> R (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1097
FT                   /note="C -> L (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1104..1107
FT                   /note="AVIP -> CCYT (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1200
FT                   /note="D -> V (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   HELIX           551..553
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           554..564
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           566..572
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           577..597
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           629..642
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           648..664
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           670..690
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           696..710
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           711..714
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   TURN            719..722
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           733..742
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   TURN            745..747
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           751..767
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           769..772
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           774..776
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           787..790
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           792..802
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   TURN            803..806
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           810..826
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   TURN            827..829
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           831..840
FT                   /evidence="ECO:0007829|PDB:6WHB"
FT   HELIX           847..862
FT                   /evidence="ECO:0007829|PDB:6WHB"
SQ   SEQUENCE   1512 AA;  164470 MW;  5CB78242295411D9 CRC64;
     MAAAAGNRAS SSGFPGARAT SPEAGGGGGA LKASSAPAAA AGLLREAGSG GRERADWRRR
     QLRKVRSVEL DQLPEQPLFL AASPPASSTS PSPEPADAAG SGTGFQPVAV PPPHGAASRG
     GAHLTESVAA PDSGASSPAA AEPGEKRAPA AEPSPAAAPA GREMENKETL KGLHKMDDRP
     EERMIREKLK ATCMPAWKHE WLERRNRRGP VVVKPIPVKG DGSEMNHLAA ESPGEVQASA
     ASPASKGRRS PSPGNSPSGR TVKSESPGVR RKRVSPVPFQ SGRITPPRRA PSPDGFSPYS
     PEETNRRVNK VMRARLYLLQ QIGPNSFLIG GDSPDNKYRV FIGPQNCSCA RGTFCIHLLF
     VMLRVFQLEP SDPMLWRKTL KNFEVESLFQ KYHSRRSSRI KAPSRNTIQK FVSRMSNSHT
     LSSSSTSTSS SENSIKDEEE QMCPICLLGM LDEESLTVCE DGCRNKLHHH CMSIWAEECR
     RNREPLICPL CRSKWRSHDF YSHELSSPVD SPSSLRAAQQ QTVQQQPLAG SRRNQESNFN
     LTHYGTQQIP PAYKDLAEPW IQVFGMELVG CLFSRNWNVR EMALRRLSHD VSGALLLANG
     ESTGNSGGSS GSSPSGGATS GSSQTSISGD VVEACCSVLS MVCADPVYKV YVAALKTLRA
     MLVYTPCHSL AERIKLQRLL QPVVDTILVK CADANSRTSQ LSISTLLELC KGQAGELAVG
     REILKAGSIG IGGVDYVLNC ILGNQTESNN WQELLGRLCL IDRLLLEFPA EFYPHIVSTD
     VSQAEPVEIR YKKLLSLLTF ALQSIDNSHS MVGKLSRRIY LSSARMVTTV PHVFSKLLEM
     LSVSSSTHFT RMRRRLMAIA DEVEIAEAIQ LGVEDTLDGQ QDSFLQASVP NNYLETTENS
     SPECTVHLEK TGKGLCATKL SASSEDISER LASISVGPSS STTTTTTTTE QPKPMVQTKG
     RPHSQCLNSS PLSHHSQLMF PALSTPSSST PSVPAGTATD VSKHRLQGFI PCRIPSASPQ
     TQRKFSLQFH RNCPENKDSD KLSPVFTQSR PLPSSNIHRP KPSRPTPGNT SKQGDPSKNS
     MTLDLNSSSK CDDSFGCSSN SSNAVIPSDE TVFTPVEEKC RLDVNTELNS SIEDLLEASM
     PSSDTTVTFK SEVAVLSPEK AENDDTYKDD VNHNQKCKEK MEAEEEEALA IAMAMSASQD
     ALPIVPQLQV ENGEDIIIIQ QDTPETLPGH TKAKQPYRED TEWLKGQQIG LGAFSSCYQA
     QDVGTGTLMA VKQVTYVRNT SSEQEEVVEA LREEIRMMSH LNHPNIIRML GATCEKSNYN
     LFIEWMAGGS VAHLLSKYGA FKESVVINYT EQLLRGLSYL HENQIIHRDV KGANLLIDST
     GQRLRIADFG AAARLASKGT GAGEFQGQLL GTIAFMAPEV LRGQQYGRSC DVWSVGCAII
     EMACAKPPWN AEKHSNHLAL IFKIASATTA PSIPSHLSPG LRDVALRCLE LQPQDRPPSR
     ELLKHPVFRT TW
//
